NET PROFIT (x1000 DKK)
EMPLOYEES
NEOGAP Therapeutics AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
1
|
162
|
852 |
| Earnings before taxes |
-3,716
|
-7,687
|
-40,451 |
| EBITDA |
-3,856
|
-3,664
|
-1,721 |
| Total assets |
68,545
|
82,049
|
42,480 |
| Current assets |
14,487
|
37,684
|
16,742 |
| Current liabilities |
5,987
|
13,507
|
2,739 |
| Equity capital |
27,812
|
32,608
|
3,991 |
| - share capital |
86
|
89
|
53 |
| Employees (average) |
17
|
14
|
14 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
40.6%
|
39.7%
|
9.4% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-5.4%
|
-9.2%
|
-93.2% |
| Current ratio |
242.0%
|
279.0%
|
611.2% |
| Return on equity (ROE) |
-13.4%
|
-23.6%
|
-1013.6% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
3
|
0
|
1 |
| Chg. No. of employees % |
21%
|
0%
|
8% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.